Anti‑VEGF outperforms panretinal photocoagulation in PDR trial — brolucizumab showed superior results
- JAMA Ophthalmology published the phase 3 CONDOR trial on April 23, showing brolucizumab beat panretinal photocoagulation for proliferative diabetic retinopathy at 54 weeks. (pmc.ncbi.nlm.nih.gov) - The clearest number is a 4.4-letter visual-acuity advantage, with 63.6% of treated eyes showing no proliferative diabetic retinopathy at week 54. (ophthalmologytimes.com) - That matters because laser is the old standard, but injections only work if patients return reliably — and brolucizumab still carries inflammation risk. (pmc.ncbi.nlm.nih.gov)
Eye doctors have had two main ways to treat proliferative diabetic retinopathy, or PDR. One is panretinal photocoagulation — basically a scatter laser that burns the oxygen-hungry peri(pmc.ncbi.nlm.nih.gov)ons, which shut down the growth signal directly. The news is that a big phase 3 trial now puts one specific injection, brolucizumab, ahead of laser on vision and disease-control measures at 54 weeks. (pmc.ncbi.nlm.nih.gov) ### What is PDR, exactly? PDR is the dangerous late stage of diabetic retinopathy. The retina gets starved of oxygen, then starts growing fragile new blood vessels that can bleed, scar, and pull the retina ap(pmc.ncbi.nlm.nih.gov). (aaojournal.org) ### Why has laser been the default for so long? Laser works, and it lasts. That is the big reason. PRP has been standard care for decades because it reduces the risk of severe vision loss without depending on frequent injections forever. But the tradeoff is real — peripheral visual field can shrink, night vision can worsen, and macular edema can flare. (ophthalmologytimes.co([pmc.ncbi.nlm.nih.gov)b-superior-to-panretinal-photocoagulation-for-proliferative-diabetic-retinopathy)) ### So what changed in CONDOR? CONDOR randomized 689 patients across 152 sites in 16 countries to either brolucizumab 6 mg or PRP. The injection arm got three loading doses every 6 weeks, then every 12 we(aaojournal.org)best-corrected visual acuity at week 54. (pmc.ncbi.nlm.nih.gov) ### How much better was brolucizumab? Not by a tiny technical margin. The study cleared noninferiority on the main endpoint and then showed superiority over PRP, with a 4.4-letter advantage in visual acuity at week 54. Disease control also looked much stronger — 63.6% of eyes in the brolucizumab group had no PDR at week 54, versus 22.4% with laser. (ophthalmologytimes.com) ### Why does that matter more than it sounds? Because PDR treatment is not just about saving the center of vision today. It is about stopping the whole disease from staying active. If more eyes actually regress out of the(pmc.ncbi.nlm.nih.gov)nd less cumulative retinal damage. A 4.4-letter average gain is not miraculous, but in a disease where laser can preserve vision while still costing field and night vision, that edge is meaningful. (ophthalmologytimes.com)ower with brolucizumab than with PRP, but intraocular inflammation and retinal vasculitis were higher — 5.2% versus 0.6%. That matters a lot because brolucizumab has had a complicated safety reputation in retinal disease before this study. (ophthalmologytimes.com) ### And what about the real-world problem? Follow-up. Anti-VEGF therapy lo(ophthalmologytimes.com)rsists, and the treatment burden is lower. Even the paper’s own takeaway is basically that drug-versus-laser choice still depends on expected visit compliance, cost, and visit frequency. (pmc.ncbi.nlm.nih.gov) ### Where does this leave treatment now? It strengthens the case that drug-first treatment for PDR can beat laser-first treatment (ophthalmologytimes.com) patients where durability and simplicity matter more. (pmc.ncbi.nlm.nih.gov) The bottom line is simple. Brolucizumab just cleared a bar that matters — not merely matching laser, but beating it on vision and disease regression. But the whole story still turns on two very unglamorous things: showing up for visits, and staying safe.
